Unique ID issued by UMIN | UMIN000035975 |
---|---|
Receipt number | R000040974 |
Scientific Title | Analysis of clinical significance of procalcitonin in small-cell lung cancer |
Date of disclosure of the study information | 2019/02/22 |
Last modified on | 2021/02/23 14:16:59 |
Analysis of clinical significance of procalcitonin in small-cell lung cancer
Procalcitonin in SCLC
Analysis of clinical significance of procalcitonin in small-cell lung cancer
Procalcitonin in SCLC
Japan |
Small cell lung cancer
Pneumology |
Malignancy
NO
To assess clinical significance of procalcitonin in small-cell lung cancer.
Others
Observational study
Exploratory
Explanatory
Not applicable
Association between the concentration of procalcitonin and overall survival in small cell lung cancer patients.
1. Association between the concentration of procalcitonin and response rate, progression-free survival in small cell lung cancer patients.
2. Association between the concentration of procalcitonin and bacterial infection.
Observational
19 | years-old | < |
99 | years-old | > |
Male and Female
Patients who receive chemotherapy and/or radiotherapy for small cell lung cancer in Niigata University Medical and Dental Hospital.
N/A
35
1st name | Satoshi |
Middle name | |
Last name | Watanabe |
Niigata University Medical and Dental Hospital
Department of Respiratory Medicine and Infectious Diseases
951-8510
1-754 Asahimachidori, Chuouku, Niigata, Japan
0253689325
satoshi7@med.niigata-u.ac.jp
1st name | Satoshi |
Middle name | |
Last name | Watanabe |
Niigata University Medical and Dental Hospital
Department of Respiratory Medicine and Infectious Diseases
951-8520
1-754 Asahimachidori, Chuouku, Niigata, Japan
0253689325
satoshi7@med.niigata-u.ac.jp
Niigata University
Niigata University
Self funding
Institutional Review Board of the Niigata University
1-757, Asahimachidori, Chuouku, Niigata, Japan
025-368-9325
sanonao@adm.niigata-u.ac.jp
NO
2019 | Year | 02 | Month | 22 | Day |
N/A
Unpublished
N/A
79
Twenty-three SCLC patients and 26 NSCLC patients were enrolled as the discovery cohort, and 30 SCLC patients were enrolled as the validation cohort. The PCT level in SCLC patients was significantly higher than that in NSCLC patients. In both the discovery and validation cohorts, the median survival time was significantly shorter in SCLC patients with PCT-high than in SCLC patients with PCT-normal (discovery; 11.7 months vs. 89.7 months, p < 0.005, validation; 9.6 months vs. 22.6 months, p < 0.005).
2021 | Year | 02 | Month | 23 | Day |
Patients who were pathologically diagnosed with SCLC and NSCLC at our institution.
We used our official institutional website as an opt-out method for the discovery cohort. Patients in the validation cohort provided written informed consent.
N/A
Serum procalcitonin, survival time
Enrolling by invitation
2012 | Year | 01 | Month | 20 | Day |
2012 | Year | 02 | Month | 06 | Day |
2012 | Year | 02 | Month | 06 | Day |
2014 | Year | 03 | Month | 31 | Day |
To assess the association between the concentration of procalcitonin and survival time in small cell lung cancer patietns.
2019 | Year | 02 | Month | 22 | Day |
2021 | Year | 02 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040974
Research Plan | |
---|---|
Registered date | File name |
2020/08/24 | プロカルシトニン研究計画.docx |
Research case data specifications | |
---|---|
Registered date | File name |
2020/08/24 | プロカルシトニン患者説明文書.docx |
Research case data | |
---|---|
Registered date | File name |
2020/08/24 | プロカルシトニン同意書.doc |